Compare RDY & AMG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RDY | AMG |
|---|---|---|
| Founded | 1984 | 1993 |
| Country | India | United States |
| Employees | N/A | 5600 |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.8B | 10.0B |
| IPO Year | 2001 | N/A |
| Metric | RDY | AMG |
|---|---|---|
| Price | $11.42 | $348.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $16.90 | ★ $384.00 |
| AVG Volume (30 Days) | ★ 3.0M | 259.7K |
| Earning Date | 05-12-2026 | 05-01-2026 |
| Dividend Yield | ★ 0.52% | 0.01% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.72 | $11.98 |
| Revenue Next Year | $3.50 | $9.34 |
| P/E Ratio | $18.67 | ★ $14.55 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.19 | $200.00 |
| 52 Week High | $15.67 | $382.75 |
| Indicator | RDY | AMG |
|---|---|---|
| Relative Strength Index (RSI) | 24.43 | 48.10 |
| Support Level | N/A | $334.20 |
| Resistance Level | $13.96 | $363.89 |
| Average True Range (ATR) | 0.36 | 12.79 |
| MACD | -0.24 | -2.78 |
| Stochastic Oscillator | 0.15 | 36.29 |
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
Affiliated Managers Group offers investment strategies to investors through its network of affiliates. The firm typically buys a majority interest in small to mid-size boutique asset managers, receiving a fixed percentage of revenue from these firms in return. Affiliates operate independently, with AMG providing strategic, operational, and technology support, as well as global distribution. At the end of March 2026, AMG's affiliate network—which includes firms like Abacus Capital and Pantheon dedicated to private markets (which accounted for 17% of AUM), AQR Capital and Capula Investment Management in liquid alternatives (29%), and Harding Loevner, Tweedy Browne, Parnassus, and Yacktman in equities, multi-asset, and bond strategies (54%)—had $882.0 billion in managed assets.